Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell"

Key Points

• Wall Street Zen downgraded Ocugen to “Sell” from “Hold,” although the broader analyst consensus remains “Moderate Buy,” with four Buy ratings and one Sell rating and a $9.50 average price target.
• Ocugen shares traded at $1.27, while the company’s latest quarter showed a wider-than-expected loss of $0.07 per share. Revenue of $1.49 million exceeded estimates, but research and development costs and overall operating expenses increased substantially.
• The company’s pipeline and financing provided positive developments, including FDA clearance for the Phase 3 OCU410 trial and a $130 million convertible-notes financing that extends its cash runway; however, the financing increases debt and potential shareholder dilution.

Ocugen (NASDAQ:OCGN - Get Free Report) was downgraded by Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday.

OCGN has been the subject of a number of other reports. Canaccord Genuity Group decreased their price target on shares of Ocugen from $12.00 to $11.00 and set a "buy" rating for the company in a report on Wednesday, May 27th. Weiss Ratings cut Ocugen from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, June 23rd. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Ocugen presently has an average rating of "Moderate Buy" and a consensus price target of $9.50.

Ocugen Trading Up 2.4%

NASDAQ:OCGN opened at $1.27 on Friday. Ocugen has a 12 month low of $0.96 and a 12 month high of $2.73. The firm has a market cap of $430.67 million, a price-to-earnings ratio of -4.88 and a beta of 2.21. The company has a quick ratio of 1.86, a current ratio of 1.86 and a debt-to-equity ratio of 4.17. The company's 50 day moving average is $1.34 and its 200-day moving average is $1.56.

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The company had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.89 million. Equities analysts anticipate that Ocugen will post -0.22 EPS for the current year.

Insider Buying and Selling

In related news, CFO Treerita Essali Johnson-Greene purchased 21,000 shares of Ocugen stock in a transaction on Monday, June 15th. The stock was purchased at an average cost of $1.23 per share, with a total value of $25,830.00. Following the acquisition, the chief financial officer directly owned 521,000 shares in the company, valued at approximately $640,830. This trade represents a 4.20% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 3.95% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. SmartHarvest Portfolios LLC acquired a new stake in Ocugen during the fourth quarter worth about $31,000. CTC Alternative Strategies Ltd. bought a new position in Ocugen during the first quarter valued at about $34,000. BNP Paribas Financial Markets raised its holdings in Ocugen by 56.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock valued at $36,000 after acquiring an additional 13,326 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Ocugen by 198.0% in the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company's stock worth $36,000 after acquiring an additional 24,460 shares during the period. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Ocugen in the 4th quarter worth approximately $38,000. Institutional investors own 10.27% of the company's stock.

Key Headlines Impacting Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source